林业发展局批准对经EGFR改变的肺癌进行第一次次皮治疗,提供更快、更安全的护理。 FDA approves first subcutaneous treatment for EGFR-mutated lung cancer, offering faster, safer care.

林业发展局已核准Rybrevant Faspro(amivantamab和hyaluronidase-lpuj)为首次对患有EGFR改型的非小型细胞肺癌的成年人进行非皮下治疗,为静脉注射疗法提供更快、更方便的替代办法。 The FDA has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first subcutaneous treatment for adults with EGFR-mutated non-small cell lung cancer, offering a faster, more convenient alternative to intravenous therapy. 根据第三期试验数据,皮下注射的药物与IV版本的药物度相匹配,并且显示无进展和整体存活率有所改善,输液相关反应和血栓减少. Based on Phase 3 trial data, the subcutaneous form matched the IV version in drug levels and showed improved progression-free and overall survival, with fewer infusion-related reactions and blood clots. 它现在被批准适用于所有治疗环境,包括与Lazcluze的第一线使用,并缩短了治疗时间,从小时到分钟。 It is now approved for all treatment settings, including first-line use with Lazcluze, and reduces treatment time from hours to minutes.